| Active substance | mirvetuximab soravtansine |
| Holder | AbbVie |
| Status | Running |
| Indication | Treatment in monotherapy of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 26/02/2025 |